Clear-cell carcinoma of the ovary

K Fujiwara; D Shintani; T Nishikawa

doi:10.1093/annonc/mdw086

Clear-cell carcinoma of the ovary

Ann Oncol. 2016 Apr:27 Suppl 1:i50-i52. doi: 10.1093/annonc/mdw086.

Authors

K Fujiwara¹, D Shintani², T Nishikawa²

Affiliations

¹ Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka-City, Japan fujiwara@saitama-med.ac.jp.
² Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka-City, Japan.

PMID: 27141072
DOI: 10.1093/annonc/mdw086

Abstract

Clear-cell carcinoma of the ovary (CCCO) is a distinct entity of epithelial ovarian cancer in terms of clinical, histopathological, or genetic features. The incidence of CCCO is different by ethnicity but the reason is not clear yet. Overall prognosis of CCCO is good because most CCCO is found in stage I. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. The same is true for recurrent disease. Therefore, genetic analysis of CCCO is important to find the right target(s) and better therapeutic approaches. Because of its rarity, international collaboration is necessary to conduct randomized clinical trials for CCCO.

MeSH terms

Adenocarcinoma, Clear Cell / drug therapy*
Adenocarcinoma, Clear Cell / mortality
Adenocarcinoma, Clear Cell / pathology
Clinical Trials as Topic
Female
Humans
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Survival Analysis
Treatment Outcome